ep
debt total capit
updat three year financi plan guid revenu acceler high singl
digit anoth cost synergi mid-teen backlog growth
believ expect higher thu mute reaction market share
continu believ multipl fair singl digit revenu growth maintain
neutral rate rais target slightli higher estim
deliv promis sinc merger announc three year
ago time manag promis acceler top line growth faster
would otherwis plu deliv run rate save exit
achiev deploy addit capit sinc close
merger includ invest softwar develop technolog infrastructur
acquisit repurchas stock deliv
compound-annual-growth-rate revenu turnov sinc merger stand view
next three year plan continu acceler revenu growth
technolog analyt initi low
end rang ramp high end oper excel
plan implement deliv addit run rate save exit
given backlog growth grow mid-teen better believ much
updat guid alreadi stock
artifici intellig machin learn creat better cro overal drug
develop spend increas per year state goal grow
industri averag aggress deliv must gain massiv share emerg
biopharma segment pipelin consist specialti biopharma orphan
drug client afford statu quo trial delay
protocol amend miss enrol target creat smarter
platform improv product cra site provid even patient
radic improv measur earli proof point show reduct
site identif reduct non-enrol site faster recruit rate
still earli client adopt oce virtual trial
chang pharma industri impact spend drug research revers
current increas outsourc trend pharma industri averag leverag
balanc sheet impact opportun
iqvia largest cro industri expertis across major therapeut
oper countri
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
revenu
revenu reimburs expens
consolid incom oper
loss extinguish debt
sale busi
incom tax
tax incom
equiti earn unconsolid affili
loss incom non-control interest
revenu
current disclosur inform compani locat
